Last reviewed · How we verify
NCT05885919: EARLYS
Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
Phase 3 trial testing Edaravone Dexborneol Concentrated Solution for injection in Ischemic Stroke, Acute in 212 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 212 |
| Start date | 1 July 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Edaravone Dexborneol Concentrated Solution for injection — full drug profile →
- Edaravone Dexborneol placebo
Conditions studied
- Ischemic Stroke, Acute — all drugs for Ischemic Stroke, Acute →
- Treatment Outcome — all drugs for Treatment Outcome →
Sponsor
Xiangya Hospital of Central South University
Who can join
Adults 18 to 80, any sex, with Ischemic Stroke, Acute or Treatment Outcome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study was to evaluate the efficacy and safety of initiation of edaravone dextivel therapy compared with placebo in patients with acute ischaemic stroke (early and late) and to explore the optimal time window for "brain cell protective therapy" of edaravone dexborneol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05885919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Edaravone Dexborneol Concentrated Solution for injection
Trials testing the same drug.
- NCT05249920 — Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2) · Phase 3 · completed
Other recruiting trials for Ischemic Stroke, Acute
Currently open trials in the same condition.
- NCT06639360 — Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke · NA · recruiting
- NCT07043686 — Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study · NA · recruiting
- NCT06920303 — Accuracy of Transcranial Colour Coded Duplex in Comparing With CT Angiography · recruiting
- NCT06712004 — A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke · Phase 2 · recruiting
- NCT06726941 — Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia · NA · recruiting
Other Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
- NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05885919 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
- Last refreshed: 27 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05885919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing